Mersana Therapeutics Stock Forecast, Price & News

-0.20 (-1.37 %)
(As of 06/17/2021 04:35 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume535,170 shs
Average Volume843,821 shs
Market Capitalization$998.21 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Mersana Therapeutics logo

About Mersana Therapeutics

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.21 out of 5 stars

Medical Sector

964th out of 2,102 stocks

Pharmaceutical Preparations Industry

469th out of 832 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

Is Mersana Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Mersana Therapeutics?

Wall Street analysts have given Mersana Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mersana Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Mersana Therapeutics

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its quarterly earnings data on Monday, May, 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.11. Mersana Therapeutics had a negative net margin of 12,779.23% and a negative trailing twelve-month return on equity of 44.42%.
View Mersana Therapeutics' earnings history

How has Mersana Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRSN shares have increased by 122.1% and is now trading at $14.35.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MRSN?

6 brokerages have issued 12 month price objectives for Mersana Therapeutics' stock. Their forecasts range from $18.00 to $33.00. On average, they expect Mersana Therapeutics' share price to reach $27.40 in the next twelve months. This suggests a possible upside of 90.9% from the stock's current price.
View analysts' price targets for Mersana Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 57, Pay $881.5k)
  • Mr. Brian C. DeSchuytner, Sr. VP of Fin. & Product Strategy (Age 43, Pay $580.01k)
  • Dr. Timothy B. Lowinger, Chief Science & Technology Officer (Age 57, Pay $606.13k)
  • Dr. Michael Kaufman, Chief Manufacturing Officer (Age 63, Pay $590.23k)
  • Dr. Arvin Yang M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 45, Pay $533.54k)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Mr. Ashish Mandelia, VP, Controller & Principal Accounting Officer (Age 47)
  • Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications
  • Ms. Alejandra Veronica Carvajal, Sr. VP & Chief Legal Officer (Age 47)
  • Ms. Carla Poulson, Chief HR Officer

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics CEO Anna Protopapas on Anna Protopapas has an approval rating of 100% among Mersana Therapeutics' employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Mersana Therapeutics' key competitors?

What other stocks do shareholders of Mersana Therapeutics own?

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (11.59%), Sarissa Capital Management LP (5.76%), Price T Rowe Associates Inc. MD (4.28%), Bellevue Group AG (4.13%), Rock Springs Capital Management LP (3.99%) and Orbimed Advisors LLC (2.72%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends for Mersana Therapeutics

Which institutional investors are selling Mersana Therapeutics stock?

MRSN stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Acuta Capital Partners LLC, Price T Rowe Associates Inc. MD, Jane Street Group LLC, Nuveen Asset Management LLC, Ghost Tree Capital LLC, Schonfeld Strategic Advisors LLC, and Credit Suisse AG. Company insiders that have sold Mersana Therapeutics company stock in the last year include Ashish Mandelia, Eva M Jack, and Timothy B Lowinger.
View insider buying and selling activity for Mersana Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Mersana Therapeutics stock?

MRSN stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sarissa Capital Management LP, Bellevue Group AG, Rock Springs Capital Management LP, CIBC Asset Management Inc, Citigroup Inc., Millennium Management LLC, and Putnam Investments LLC. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, and Lawrence M Alleva.
View insider buying and selling activity for Mersana Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $14.35.

How much money does Mersana Therapeutics make?

Mersana Therapeutics has a market capitalization of $998.21 million and generates $830,000.00 in revenue each year. The company earns $-88,040,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

Mersana Therapeutics employs 110 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is

Where are Mersana Therapeutics' headquarters?

Mersana Therapeutics is headquartered at 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.